Cinnamic aldehyde treatment alleviates chronic unexpected stress-induced depressive-like behaviors via targeting cyclooxygenase-2 in mid-aged rats by Yao, Ying et al.
Research Paper
Cinnamic aldehyde treatment alleviates chronic unexpected
stress-induced depressive-like behaviors via targeting
cyclooxygenase-2 in mid-aged rats
Ying Yao a, Hai-Ying Huang b, Yuan-Xiao Yang c, Jian-You Guo d,n
a Pharmacy Department, Zhejiang Medical College, Hangzhou 310053, China
b School of Pharmacy, Henan University of Traditional Chinese Medicine, Zhengzhou 450046, China
c School of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China
d Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, 16# Lincui Road, Chaoyang District, Beijing 100101, China
a r t i c l e i n f o
Article history:
Received 6 September 2014
Received in revised form
21 December 2014
Accepted 23 December 2014
Available online 1 January 2015
Keywords:
Aged
Depression
Cinnamic aldehyde
Cyclooxygenase-2
Prostaglandin E2
a b s t r a c t
Ethnopharmacological relevance: COX-2 has been considered as a potent molecular target for prevention
and therapy of depression. However, a recent study showed that COX-2 inhibitor does not improve
depressive symptoms in persons aged 70 and over. Therefore, whether treatments targeting COX-2 have
a clinical efﬁcacy in depression, especially elderly individuals, remains unclear. Cinnamic aldehyde is a
major constituent of Cinnamomum cassia, which has exhibited excellent anti-inﬂammatory activities as a
COX-2 inhibitor. To investigate the potential antidepressant effect of cinnamic aldehyde in mid-aged rats.
Materials and methods: The depressive-like behaviors were measured after the rats exposed to chronic
unexpected mild stress (CUMS). Cinnamic aldehyde was administrated by oral gavage to stressed rats
(22.5, 45, 90 mg/kg, respectively) for 21 days. The mRNA, protein expression and activity of
cyclooxygenase-2 (COX-2), as well as prostaglandin E2 (PGE2) levels were measured in the frontal cortex
and hippocampus of stressed animals.
Results: We found that CUMS procedure not only decreased the sucrose preference, but also elevated the
COX-2 activity, mRNA and protein levels, and increased PGE2 concentration in rat brain regions.
Treatment with high doses of cinnamic aldehyde (45, 90 mg/kg) reversed the behavioral abnormalities,
and decreased the COX-2 protein and activity (but not COX-2 mRNA expression) and PGE2 concentration
in frontal cortex and hippocampus of stressed rats.
Conclusion: Cinnamic aldehyde exerted antidepressant-like effects in stressed mid-aged rats, and its
mechanism of action appears to decrease COX-2 protein and activity. The current ﬁndings suggest that
targeting COX-2 system might be beneﬁt to the depression, especially elderly individuals and cinnamic
aldehyde might be a promising medicine to treat the subjects in the depression.
& 2014 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Depression may become one of the principal leading causes of
disease burden by 2030 according to the World Health Organization
(WHO). Thus, the discovery of antidepressants is urgent and attrac-
tive, and could arouse considerable impacts on worldwide (Lee et al.,
2014). Monoamines play an important role in the pathophysiology of
depression, and recent treatment chosen for depression have mainly
focused on medications which change the activity of monoamine
neurotransmitter systems (Hasler, 2010). However, the monoami-
nergic theory of illness has failed to ﬁnd novel antidepressants
beyond the limited therapeutic methods currently available (Brigitta,
2002). There is now a clear body of recent evidence to support an
etiologic role for other factors in the pathophysiology of depression,
especially activation of the inﬂammatory system (Pace et al., 2007;
Schiepers et al., 2005). Serum proinﬂammatory cytokines are
increased in individuals with major depression and levels of these
cytokines may reﬂect depression severity (Duman and Voleti, 2012;
Szelenyi and Selmeczy, 2002).
One inﬂammatory pathway implicated in major depression is the
conversion of arachidonic acid (AA) to prostaglandins by the enzyme
cyclooxygenase (COX). COX exists in two types of isoforms: COX-1,
which is stably expressed and is cytoprotective; and COX-2, which is
inducible by cytokines and promotes further inﬂammation (Ricciotti
and FitzGerald, 2011). Clinical trails have showed that adjunctive COX-
2 inhibition with celecoxib is beneﬁcial in treating depression (Muller
et al., 2006; Nery et al., 2008). We also found celecoxib reverses
chronic unpredictable stress-induced depressive-like behaviors in rats
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(Guo et al., 2009). Therefore, treatments targeting COX-2 should have
a clinical efﬁcacy in depression. However, a recent study showed that
COX-2 inhibitor does not improve depressive symptoms in persons
aged 70 and over (Fields et al., 2012). Therefore, whether treatments
targeting COX-2 have a clinical efﬁcacy in depression, especially
elderly individuals, remains unclear.
Cinnamomum cassia (Lauraceae) is a kind of deciduous tree that
grows in Korea, China, and Japan, which has long been ethnophar-
macologically used as a folk medicine to treat various inﬂammatory
diseases (Seo et al., 2005; Yu et al., 2012). Its extracts contain several
active components such as cinnamic aldehyde, cinnamic alcohol,
cinnamic acid, and coumarin. As a major and effective compound
isolated from Cinnamomum cassia, cinnamic aldehyde decreased
carrageenan-induced COX-2 expression in the edema paw (Liao
et al., 2012). We also found that cinnamic aldehyde reduced IL-1β-
induced COX-2 activity in rat cerebral microvascular endothelial
cells. These ﬁndings suggest that cinnamic aldehyde has excellent
anti-inﬂammatory activities as a COX-2 inhibitor (Guo et al., 2009).
Based on the above foundings, in the present study we inves-
tigated the effects of cinnamic aldehyde in 18 months old rats
following by 21 days chronic unpredictable mild stress (CUMS).
Considering the life-span of Sprague-Dawley rats is 2.5–3.5 years, 18
months old rats is roughly equivalent to the human age of 50 to 55
(mid-age) (Shi, 1999). Cinnamic acid was orally administered to the
stressed mid-aged rats for 21 days during the CUMS treatment. The
potential antidepressant effect of cinnamic aldehyde was then
clariﬁed by sucrose preference test and open ﬁeld test. In addition,
levels of COX-2 activity, protein, and mRNA, and prostaglandin E2
(PGE2, a major COX-2-mediated inﬂammatory mediator) concen-
tration in frontal cortex and hippocampus were also detected.
2. Methods and materials
2.1. Materials
Cinnamic aldehyde (99%) was provided by School of Pharmaceu-
tical Sciences in Peking University, which was isolated from Cinna-
momum cassia. Fluoxetine hydrochloride was from Changzhou Siyao
Pharmaceuticals Co., Ltd. (Changzhou, PR China). PGE2 enzyme-
linked immunosorbent assay (ELISA) kit was purchased from Invitro-
gen Biomedical Co. (Carlsbad, CA). COX ELISA kit was purchased from
Cayman Chemical Co. (Ann Arbor, MI). TRIzol, Reverse Transcription
Reagents, SYBR Green PCR Master Mix and electrophoresis reagents
were obtained from Takara Co. (Tokyo, Japan). All other materials
were purchased from Sigma Co. (St. Louis, MO).
2.2. Animals
Male Sprague-Dawley rats aged 18 months were obtained from
Beijing Weitong Lihua Research Center for Experimental Animals.
Rats were kept on a 12:12 h in the light: dark cycle (lights on at
7:00 A.M., lights off at 7:00 P.M.) in individual home cages with food
and water available ad libitum except as described in stress.
The research was conducted in accordance with the interna-
tionally accepted principles for laboratory animal use and care of
the European Community guidelines (EEC Directive of 1986; 86/
609/EE). Experimental procedures were approved by the Institu-
tional Animal Care and Use Committee of the Institute of Psychol-
ogy of the Chinese Academy of Sciences. All efforts were made to
minimize animal suffering and to use only the number of animals
necessary to produce reliable scientiﬁc data.
2.3. Groups and treatment
Sixty rats were equally assigned into ﬁve groups: chronic
unpredictable mild stress group, cinnamic aldehyde groups (22.5,
45 and 90 mg/kg) and ﬂuoxetine group. The groups and treatments
are shown in Table 1. Animals were administrated with correspond-
ing drugs for 21 days during the 21-day exposure to CUMS. Twelve
separate rats administrated with an equal volume of distilled water
were used as a control. Fluoxetine and cinnamic aldehyde were
diluted in distilled water and given one hour before the stress
exposure. All drugs were prepared immediately before use and
were given orally in a volume of 0.5 mL/100 g body weight with a
rat gavage needle (length 10 cm).The treatment protocol of doses
and administration route used for cinnamic aldehyde and ﬂuoxetine
were adopted according to previous studies (Lou et al., 2010; Song
et al., 2013).
2.4. Chronic unpredictable stress procedure
The chronically stress procedure was described previously (Guo
et al., 2009). Brieﬂy, rats were exposed to different stressors daily
for 21 days as follows. day1: cold immobilization for 1 h at 4 1C,
forced swim for 30 min at 25 1C; day 2: immobilization for 1 h,
crowding for 23 h; day 3: forced cold swim stress for 5 min at 10 1C,
isolation (Each rat was placed in a closed chamber) for 23 h; day 4:
immobilization for 1 h, vibration for 1 h; day 5: forced swim stress
for 30 min at 25 1C, cold immobilization for 1 h at 4 1C; day 6:
forced cold swim stress for 5 min at 10 1C, crowding (Six rats were
placed in a cage) for 23 h; day 7: vibration for 1 h, isolation for 23 h.
This schedule was repeated twice for a total of 21 days. Prior to the
study, certain criteria were set for excluding animal on weight loss,
or the possible occurrence of wounds. Rats were acclimated to
3 min of handling once a day for 7 consecutive days before being
used in experiment and were weighed on the 1st and 7th day of
handling.
2.5. Sucrose preference test
Sucrose preference tests were used to operationally deﬁne
anhedonia. Speciﬁcally, anhedonia was deﬁned as a reduction in
sucrose intake and sucrose preference relative to the intake and
preference of the control group. A sucrose preference test consisted
of ﬁrst removing the food and water from each rat's cage for a period
of 20 h. Water and 1% sucrose were then placed on the cages in
preweighed glass bottles, and animals were allowed to consume the
ﬂuids freely for a period of 1 h. Two baseline preference tests were
Table 1
Groups and treatments.
Groups Treatment Drug Dose (mg/kg)
Control No treatment Distill water –
CUMS CUMS Distill water –
CUMSþCinnamic aldehyde (22.5 mg/kg) CUMS Cinnamic aldehyde 22.5
CUMSþCinnamic aldehyde (45 mg/kg) CUMS Cinnamic aldehyde 45
CUMSþCinnamic aldehyde (90 mg/kg) CUMS Cinnamic aldehyde 90
CUMSþﬂuoxetine (10 mg/kg) CUMS Fluoxetine 10
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performed, separated by at least 5 days, and the results were
averaged. A preference test was also conducted following the 21
days chronic unpredictable stress period. On the last-stressed day,
rats were deprived of water and food for 20 h, then from the next day
on, rats were given a 1 h window sucrose preference test (24 h after
the last drug treatment). Sucrose and water consumption (ml) was
measured and the sucrose preference was calculated as the suc-
rose preference (%)¼sucrose consumption /(sucrose consumptionþ
water consumption).
2.6. Open ﬁeld exploratory behavior test
Open ﬁeld test was used to study the exploratory and anxiety
behavior of rats and was performed after the sucrose preference test.
The open ﬁeld apparatus consisted of a square arena 6060 cmwith
40 cm high wall. The entire apparatus was painted black except for
6 mmwhite lines that divided the ﬂoor into 16 equal size squares. The
squares were subdivided into peripheral and central sector, where the
central sector included the 4 central squares (22) and the periph-
eral sector contained the squares close to the wall. The apparatus was
illuminated with a low intensity diffuse light (45W, 200 lux in the
center area) situated 45 cm above the ﬂoor level. Entire room, except
the open ﬁeld, was kept dark during the experiment. Each animal was
placed in the central square and observed for 5 min by a video camera
and taped for further analysis. Motility was scored when an animal
crossed a sector border with both its hind-limbs. The following
behaviors were scored by an observer who was blind to the drug
treatment. Central ambulation: number of central squares crossed;
Total ambulation: the overall number of peripheral and central square
crossed; rearing: number of times the animal stood on its hind limbs;
grooming: number of times the animal made these responses viz.
grooming of the face, licking/cleaning and scratching the various parts
of the body. Immobility period: the time spent immobile. Anxiety-
related behavior was measured by the percentage of central ambula-
tion and calculated as the percentage of central ambulation (%)¼
central ambulation/total ambulation. Between tests, the apparatus
was cleaned with 5% alcohol.
2.7. Brain sample collection
After the last behavior tests, all rats were decapitated between
11:00 A.M. and 1:00 P.M. to avoid ﬂuctuation of hormone levels.
The frontal cortex and hippocampus in each hemisphere were
rapidly separated on ice-plate and stored at 80 1C until analysis.
2.8. Measurement of COX-2 activity
COX activity was determined by the method of Bosetti et al.
(2002) with modiﬁcations. The frontal cortex and hippocampus
brain regions were homogenized in lysate buffer (10 mM Tris-HCl,
pH 7.8, containing 1% Nonidet P-40, 0.15 M NaCl, and 1 mM EDTA),
then chilled on ice for 30 min and centrifuged at 10,000 rpm for
15 min. Then supernatant was collected and the COX activity was
determined by enzyme-linked immunosorbent assay (ELISA) as
indicated in kit instructions (Cayman, Ann Arbor, MI). The kit
includes isozyme-speciﬁc inhibitors for distinguishing COX-2
activity from COX-1 activity. The COX-2 activity was expressed as
nmol/min/mg wet weight of tissue.
2.9. Western blotting
The frontal cortex and hippocampus were put into chilled tubes
treated with an enzyme inhibitor. Brain tissue was homogenized
and Western blot analysis carried out as previously reported
(Guo et al., 2009), using primary antibodies for COX-2 (1:2000,
Santa Cruz Biotechnology) and β-actin (1:10,000, Santa Cruz
Biotechnology). A secondary antibody conjugated with horserad-
ish peroxidase (HRP, 1:5000, Bio-Rad) was used. Immunoblots
were visualized on X-ray ﬁlm by chemiluminescence reaction
(Pierce), and image analysis was performed on optical densitycali-
brated images by AlphaEase Stand Alone software (Alpha
Innotech).
2.10. Total RNA isolation and real time RT-PCR
Total RNA from frontal cortex and hippocampus was extracted
using the TRIzol method, then reverse transcribed to cDNA using
the Taqman Reverse Transcription Reagents. The relative COX-2
mRNA expression values were normalized to the expression value
of GAPDH. The sequences for primers were: COX-2-forward 50-
TTTGTTGAGTCATTCACCAGACAGAT-30 and reverse 50-ACGATGTG-
TAAGGTTTCAGGGAGAAG-30(169 bp); GAPDH-forward 50-TGAACGG-
GAAGCTCACTGG-30 and reverse 50-GAGCTTCACAAAGTTGTCATTG-
AG-30(260 bp. PCR conditions were as follow: 95 1C for 30 s to
activate the iTaq polymerase, 45 cycles of 5 s at 95 1C and 31 s at
60 1C. Melt curve was performed for all samples. Relative contents
of the COX-2 genes were calculated using the ddCt method (2–ddCt)
as described by Schmittgen et al. (2000).
2.11. Measurement of PGE2 concentration
Levels of PGE2 were determined in microwaved brain extracts.
Hippocampus and frontal cortex were weighed, and then extracted
in 18 volumes of hexane: 2-propanol (3:2, by volume) using a glass
Tenbroeck homogenizer. The prostaglandins were puriﬁed from the
lipid extract using a C18 Sep-Pak cartridge (Waters). The concentra-
tion of PGE2 was determined using an ELISA kit (Invitrogen,
Carlsbad, CA) and expressed as ng/g wet weight of tissue.
2.12. Statistical analysis
The results were analyzed by the Kruskal–Wallis test and
Dunn's multiple comparisons test. All data are presented as the
means7standard error of the mean. Differences were considered
signiﬁcant at Po0.05.
3. Results
3.1. Effects of cinnamic aldehyde on sucrose preference
Before the CUMS procedure, there was no signiﬁcant difference
in sucrose solution intake and sucrose preference among groups
(all P40.05, data not shown). The liquid intake and preference for
sucrose in six groups following 21 days of chronic unpredictable
stress were shown in Fig. 1A and B. The Kruskal–Wallis test
indicated that both the sucrose solution intake and the sucrose
preference signiﬁcantly differed among groups (H¼17.28, df¼5,
N¼72, Po0.01; and H¼22.13, df¼5, N¼72, Po0.01). Compared
with control group, rats exposed to 21-day chronic unpredictable
stress exhibited a signiﬁcantly decrease in sucrose preference and
sucrose solution intake (both Po0.01), which is a key indicative of
operationally deﬁned anhedonia. Cinnamic aldehyde treatment
(45, 90 mg/kg) markedly reversed the CUMS-induced decrease in
sucrose preference (both Po0.05) and sucrose solution intake
(both Po0.05) in a dose-dependent manner. Fluoxetine treatment
also increased the stress-induced sucrose preference and sucrose
solution intake (both Po0.05). The total liquid intake did not
differ among groups (all P40.05).
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3.2. Effects of cinnamic aldehyde open ﬁeld exploratory behavior test
Kruskal–Wallis test indicated signiﬁcant differences among
groups in the total ambulation (H¼27.76, df¼5, N¼72, Po0.01),
percentage of center ambulation (H¼24.71, df¼5, N¼72, Po0.01),
rearing (H¼40.31, df¼5, N¼72, Po0.01), grooming (H¼29.14,
df¼5, N¼72, Po0.01) and immobility period (H¼43.83, df¼5,
N¼72, Po0.01). Compared with control rats, chronic stressed rats
showed the signiﬁcant decreases in total ambulation, percentage
of center ambulation, rearing, and the marked increases in
grooming and immobility period (all Po0.01). Cinnamic aldehyde
treatment (45 mg/kg and 90 mg/kg) alleviated the CUMS-induced
behavioral alterations in a dose-dependent manner, as observed
by increased total ambulation (Po0.05 and Po0.01), percentage
of central ambulation (Po0.05 and Po0.01), rearing (Po0.05 and
Po0.01), decreased grooming (both Po0.05) and immobility
period (Po0.05 and Po0.01). Fluoxetine treatment also affected
the stress-induced behavior alterations in open ﬁeld test (Table 2).
3.3. Effects of cinnamic aldehyde on COX-2 activity
The Kruskal–Wallis analysis indicated that COX-2 activity sig-
niﬁcantly differed among groups (Frontal cortex: H¼25.53, df¼5,
N¼72, Po0.01; Hippocampus: H¼21.20, df¼5, N¼72, Po0.01).
Compared with the control group, COX-2 activity was signiﬁcantly
increased in frontal cortex and hippocampus after CUMS proce-
dure (both Po0.01, Fig. 2). Chronic cinnamic aldehyde treatment
(45 mg/kg and 90 mg/kg) reversed the stress-induced COX-2
activity both in frontal cortex (Po0.05 and Po0.01, respectively)
and hippocampus (Po0.05 and Po0.01, respectively). Fluoxetine
treatment slightly reduced the COX-2 activity in stressed rats
(Frontal cortex: P¼0.062; Hippocampus: P¼0.071, respectively).
3.4. Effects of cinnamic aldehyde on COX-2 protein
We further measured the COX-2 protein level in the frontal cortex
(Fig. 3A) and hippocampus (Fig. 3B). Kruskal–Wallis test indicated
that COX-2 protein signiﬁcantly differed among groups (Frontal
cortex: H¼26.30, df¼5, N¼72, Po0.01; Hippocampus: H¼25.67,
df¼5, N¼72, Po0.01). Compared with the control rats, 21-day
stressed rats showed a signiﬁcant increase in COX-2 protein level in
frontal cortex (Po0.01) and hippocampus (Po0.01). Chronic cin-
namic aldehyde treatment (45 mg/kg and 90 mg/kg) reduced the
stressed-induced COX-2 protein level both in frontal cortex (Po0.05
and Po0.01, respectively) and hippocampus (Po0.05 and Po0.01,
respectively). Fluoxetine treatment also signiﬁcantly decreased the
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Fig. 1. Effect of cinnamic aldehyde on sucrose preference test following 21 days of
chronic unpredictable stress. Sucrose solution intake and sucrose preference was
reduced in the chronic unpredictable stress group compared with control group
(Po0.01). Cinnamic aldehyde treatment signiﬁcantly augmented the decrease in
sucrose solution intake and sucrose preference in a dose-dependent manner.
Fluoxetine treatment also increased the sucrose solution intake and sucrose
preference in stressed rats. The total liquid intake did not differ among any groups.
Data were expressed as mean7SEM (n¼12). * and # indicates statistical signiﬁ-
cance in comparison to control and chronic unpredictable stress groups respec-
tively and denotes *,# Po0.05 and **, ## Po0.01.
Table 2
Effect of cinnamic aldehyde on open ﬁeld exploratory test in chronic unpredictable stress rats.
Groups Total ambulation Central ambulation (%) Rearing Grooming Immobility period (s)
Control 39.376.6 32.175.1 21.972.8 5.271.6 100.5715.1
CUMS 21.873.7b 17.174.1b 12.471.6b 10.171.9b 232.6736.2b
CUMSþCinnamic aldehyde (22.5 mg/kg) 25.173.5 21.374.1 15.272.3 9.371.2 207.1736.9
CUMSþCinnamic aldehyde (45 mg/kg) 29.374.3c 24.874.2c 17.272.4c 7.071.6c 179.1726.7c
CUMSþCinnamic aldehyde (90 mg/kg) 32.678.8d 30.173.7d 20.571.9d 6.471.1c 159.3720.9d
CUMSþﬂuoxetine (10 mg/kg) 30.574.9c 25.474.1c 18.071.5c 6.271.1c 177.1720.1c
Data are expressed as mean7S.E.M of 12 rats per group. a, b Signiﬁcantly different from control group value (a, Po0.05; b, Po0.01). c, d Signiﬁcantly different from chronic
unpredictable stress group value (c, Po0.05; d, Po0.01).
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Fig. 2. Effect of cinnamic aldehyde on brain COX-2 activity following 21 days of
chronic unpredictable stress. The COX-2 activity was signiﬁcantly increased both in
frontal cortex (A) and hippocampus (B) after chronic unpredictable stress
(Po0.01). Cinnamic aldehyde treatment signiﬁcantly reduced the stress-induced
COX-2 activity in a dose-dependent manner. Fluoxetine treatment slightly reduced
the stress-induced COX-2 activity (P40.05). Data were expressed as mean7SEM
(n¼12). * and # indicates statistical signiﬁcance in comparison to control and
chronic unpredictable stress groups respectively and denotes *,# Po0.05 and **, ##
Po0.01.
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COX-2 protein level in the stressed rats (Frontal cortex: Po0.05;
Hippocampus: Po0.05, respectively).
3.5. Effects of cinnamic aldehyde on COX-2 mRNA expression
COX-2 mRNA expression was also detected in the frontal cortex
and hippocampus. As shown in Fig. 4 A and B, the Kruskal–Wallis test
revealed that COX-2 protein signiﬁcantly differed among groups
(Frontal cortex: H¼18.29, df¼5, N¼72, Po0.01; Hippocampus:
H¼20.52, df¼5, N¼72, Po0.01). Compared with the control group,
COX-2 mRNA expression in the stressed rats was signiﬁcantly
increased about 4 times in the frontal cortex and hippocampus after
CUMS procedure (both Po0.01). However, cinnamic aldehyde treat-
ment did not affect the stress-induced upregulation in COX-2 mRNA
expression (P40.05). Fluoxetine treatment signiﬁcantly reduced the
COX-2 mRNA expression in stressed rats (Frontal cortex: Po0.05;
Hippocampus: Po0.05, respectively).
3.6. Effects of cinnamic aldehyde on PGE2 levels
The effects of cinnamic aldehyde and ﬂuoxetine on PGE2 content
in the frontal cortex and hippocampus were shown in Fig. 5A and
Fig. 5B. The Kruskal–Wallis test indicated that PGE2 level signiﬁcantly
differed among groups (Frontal cortex: H¼20.49, df¼5, N¼72,
Po0.01; Hippocampus: H¼19.75, df¼5, N¼72, Po0.01). Compared
with control, stressed rats showed a signiﬁcantly increase in PGE2
concentration both in frontal cortex (Po0.01) and hippocampus
(Po0.01). Chronic treatment with 45 mg/kg and 90 mg/kg cinnamic
aldehyde signiﬁcantly attenuated CUMS-induced increase in PGE2
both in frontal cortex (Po0.05 and Po0.01, respectively) and
hippocampus (Po0.05 and Po0.01, respectively). Fluoxetine also
markedly reduced the stress-induced PGE2 concentration both in
frontal cortex and hippocampus (both Po0.05).
4. Discussion
In the present study, we investigated the effects of cinnamic
aldehyde on depression-like behaviors in the mid-aged rats exposed
to 21-day CUMS. The sucrose preference and open ﬁeld exploratory
tests were used to assess the depression levels in animal. After the
behavioral test, the COX-2 mRNA, protein expression and activity as
well as PGE2 concentration in the hippocampus and frontal cortex
were measured. The results showed that cinnamic aldehyde treat-
ment at a daily dosage of 45 and 90 mg/kg but not 22.5 mg/kg
exhibited a potential antidepressant effect on CUMS-produced
depression in mid-aged rats. At the meanwhile, cinnamic aldehyde
led to a decrease in COX-2 activity reactivity, protein expression and
PGE2 concentration without any effect on the COX-2 mRNA level in
the CUMS-treated rats.
Depression is the most common psychiatric disease in the
elderly, with a prevalence ranging from 22 to 46% in patients over
60 years old (Lebowitz et al., 1997). This phenomenon is getting
attention recently since the world's geriatric population is impor-
tantly increasing (Mendlewicz, 1998). In the previous study Herrera-
Pérez et al. found that a higher percentage of middle-aged rats
developed anhedonia as compared with young adult ones (Herrera-
Perez et al., 2008). Of particular interest to this study is aim to
investigate antidepressant effect of cinnamic aldehyde in mid-aged
rats. An animal model of depression in mid-aged rat followed by 21
days CUMS has been developed to simulate the pathogenesis of
depression in elderly humans. However, as the rat was individually
housed, there may be an overlap between isolation- and CUMS-
Fig. 3. Effect of cinnamic aldehyde on brain COX-2 protein level following 21 days
of chronic unpredictable stress. A. Representative immunoblots of COX-2 and β-
actin in prontal cortex and hippocampus. 1, control; 2, chronic unpredictable stress;
3, chronic unpredictable stress plus cinnamic aldehyde (22.5 mg/kg); 4, chronic
unpredictable stress plus cinnamic aldehyde (45 mg/kg); 5, chronic unpredictable
stress plus cinnamic aldehyde (90 mg/kg); 6, chronic unpredictable stress plus
ﬂuoxetine (10 mg/kg). B. Relative optical density (OD) of COX-2 to β-actin in prontal
cortex and hippocampus. Data were expressed as mean7SEM (n¼12).* and #
indicates statistical signiﬁcance in comparison to control and chronic unpredictable
stress groups respectively and denotes *,# Po0.05 and **, ## Po0.01.
0.0
0.1
0.2
0.3
0.4
0.5
control
CUMS+ cinnamic aldehyde 45 mg/kg
**
CUMS
CUMS+ cinnamic aldehyde 22.5mg/kg
CUMS+ cinnamic aldehyde 90 mg/kg
CUMS + fluoxetine 10 mg/kg
#
C
O
X-
2 
m
R
N
A
 e
xp
re
ss
io
n
 (C
O
X-
2/
G
A
PD
H
)
0.0
0.1
0.2
0.3
0.4
0.5
control
CUMS+ cinnamic aldehyde 45 mg/kg
**
CUMS
CUMS+ cinnamic aldehyde 22.5mg/kg
CUMS+ cinnamic aldehyde 90 mg/kg
CUMS + fluoxetine 10 mg/kg
#
C
O
X-
2 
m
R
N
A
 e
xp
re
ss
io
n
 (C
O
X-
2/
G
A
PD
H
)
frontal cortex 
hippocampus
Fig. 4. Effect of cinnamic aldehyde on brain COX-2 mRNA expression following 21
days of chronic unpredictable stress. The COX-2 mRNA expression in chronic
unpredictable stress group was signiﬁcantly increased both in frontal cortex
(A) and hippocampus (B) than these in the control level (Po0.01). Cinnamic
aldehyde treatment did not affect the stress-induced upregulation of COX-2 mRNA.
Fluoxetine treatment signiﬁcantly reduced COX-2 mRNA expression in stressed rats
(Po0.05). Data were expressed as mean7SEM (n¼12).* and # indicates statistical
signiﬁcance in comparison to control and chronic unpredictable stress groups
respectively and denotes *,# Po0.05 and **, ## Po0.01.
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induced depression. After the CUMS paradigm, behavioral tests were
performed by the sucrose preference and open ﬁeld tests. The
sucrose preference test is an indicator of anhedonia-like behavioral
change, which a key symptom of major depression among humans
(Willner, 1997). As described in the result section, stressed rats
consumed less sucrose solution compared to control rats. Rats
followed by 21-day chronic unpredictable stress also showed
anxious behaviors which is proved by decreased ambulation, rear-
ing, increased grooming and immobility period in the open ﬁeld
exploratory test.
Inﬂammation has been considered as a biological risk factor for
late-life depression (Krishnan, 2002). Prostaglandins, especially
PGE2, play an important role in the generation of the inﬂammatory
response. The biosynthesis of PGE2 is signiﬁcantly increased in
various inﬂamed tissues, and which contributes to the develop-
ment of the important signs of inﬂammation (Ricciotti and
FitzGerald, 2011). COX is a rate-limiting enzyme in the metabolism
of arachidonic acid to prostaglandins. COX-2 as the key inﬂamma-
tory enzyme was increased in chronic stress-induced young rat in
the previous study (Guo et al., 2009). However, whether COX-2
expression was also increased in the aged depression animal
remains unclear. Recent clinical and animal studies of depression
have focused on the brain region of frontal cortex and hippocam-
pus, which are key brain regions structurally and functionally
inﬂuenced by stress responses and critically involved in the
regulation of mood and learning/memory function (Hastings
et al., 2004; Rocher et al., 2004). In the present study, we ﬁrst
study the COX-2 expression in the hippocampus and frontal cortex
in chronic stress-induced middle aged rat. We found that the
protein, mRNA and activity of COX-2 were increased in chronic
stress-induced mid-aged rats. In addition, COX-1 activity was also
measured in the present study. We found that CUMS procedure
did not affect COX-1 activity (data not shown).The concentration of
PGE2, a bioactive metabolite of arachidonic acid (AA) induced by
COX enzyme, was also enhance by CUMS treatment in the
hippocampus and frontal cortex regions.
Cinnamomum cassia is a representative ethnoherbal medicine that
has been widely used for treating dyspepsia, gastritis, and other
inﬂammatory diseases (Hong et al., 2002). Cinnamic aldehyde is a
major constituent of Cinnamomum cassia, which is also widely
distributed in various fruits, vegetables and ﬂowers. Cinnamic alde-
hyde has been known to have various biological activities including
anti-inﬂammatory, antioxidant and anti-bacterial properties (Youn
et al., 2008). To elucidate the mechanisms underlying the potential
antidepressant effects of cinnamomum cassia, we observed the
changes of liquid intake, sucrose preference, behavioral alterations,
COX-2 expression, PGE2 concentration in chronic unpredictable stress
plus chronic cinnamomum cassia treatment in the mid-aged rat. The
results revealed that chronic cinnamomum cassia treatment could
elevate the stress-induced decrease in sucrose solution intake, sucrose
preference, and reverse the stress-induced behavioral alterations in a
dose-dependent manner. We also found that chronic cinnamic
aldehyde treatment reduced COX-2 protein and its enzymatic activity
but not its mRNA level in rat brain. Furthermore, chronic cinnamic
aldehyde treatment reduced the brain concentration of PGE2, thus
down-regulating a key downstream step in the AA cascade. COX-2
mRNA possesses ‘AUUUA' motifs in its 3'-untranslated region that
produce post-transcriptional control of COX-2 expression by acting as
translation inhibitory element or as mRNA instability determinant
(Dixon et al., 2000; Kujubu et al., 1991). Many ‘instable' messages in
the 3'-untranslated region carry motifs that might control transla-
tional efﬁciency via reversibly binding to nuclear or cytosolic factors
(Bosetti et al., 2002; Hla and Neilson, 1992). Cinnamic aldehyde might
directly bind to COX-2. Several residues have been reported to be
involved in binding of selective COX-2 inhibitors, such as His90,
Arg120, Phe518, Tyr385, and Ser530 (Murias et al., 2004). Cinnamic
aldehyde might bind to one of these binding sites and affect COX-2
mRNA stability and translation. Chronic cinnamic aldehyde treatment,
either directly or indirectly, could affect the interactions between
these RNA and protein. Cinnamic aldehyde's post-transcriptional
effect on COX-2 system could also be mediated by reduced formation
of the PGE2 that mitigates COX-2 mRNA decay and inhibition of
protein translation, normally mediated by the 3'-untranslated region
of COX-2 mRNA.
To reduce the number of animals used, the effect of cinnamic
aldehyde on control rats was not investigated in the present study.
Antidepressants usually do not induce any signiﬁcant changes on
behaviors in control animals which the depression have not yet
been developed. Furthermore, the key symptom of depression is
anhedonia and sucrose preference test was alwasys used to
operationally deﬁne anhedonia. The values of sucrose preference
in unstressed control animals are normally about 90% and these
values are very hard to be elevated further by the drug treatment
on unstressed control animals. These results have been showed in
our and other studies (Guo et al., 2009; Mao et al., 2011).
The current ﬁndings support the previous results that targeting
cyclooxygenase-2 is a viable therapeutic approach for depression (Li
et al., 2013; Muller et al., 2006). However, Fields et al. reported a
randomized controlled trial of NSAID treatment in over 2500 older
adults, the results showed that COX-2 inhibitor celecoxib could not
improved depressive symptoms over time compared with placebo.
Possible reasons for the discrepancy may that the dosage of COX-2
inhibitor used by Fields et al. (2012) may not reach the therapeutic
level. Alternatively, the mid-aged rats but not aged rats may
sensitive to COX-2 inhibitor treatment. Considering COX-2 expres-
sion may change over the course of life, it will be very interesting to
measure this protein level in immature, mature, middle-aged and
aged rats and then analyze the effect of cinnamic aldehyde in
depression rat at the different age. Besides, it should be noted that
PGE2 is a key mediator of inﬂammation in the depression. Other
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Fig. 5. Effect of cinnamic aldehyde on brain PGE2 level following 21 days of chronic
unpredictable stress. The PGE2 concentration in chronic unpredictable stress group
was signiﬁcantly increased both in frontal cortex (A) and hippocampus (B) than
these in the control level (Po0.01). Chronic treatments with cinnamic aldehyde
signiﬁcantly reduced the stress-induced PGE2 concentration in a dose-dependent
manner. Fluoxetine treatment also signiﬁcantly reduced the stress-induced PGE2
concentration (Po0.05). Data were expressed as mean7SEM (n¼12). * and #
indicates statistical signiﬁcance in comparison to control and chronic unpredictable
stress groups respectively and denotes *,# Po0.05 and **, ## Po0.01.
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proinﬂammatory cytokines such as interleukin( IL)-1β, IL-6 and
tumor necrosis factor (TNF)-α are also increased in CUMS rat and
depressive symptoms in human (Frommberger et al., 1997; Liu et al.,
2014). The effect of cinnamic aldehyde on these cytokines deserved
to be measured in the future study.
In conclusion, the present study investigated the antidepressant-
like effects and the potential mechanisms of cinnamic aldehyde in the
CUMS model of mid-aged rats. The CUMS procedure elevated COX-2
activity, protein and mRNA expression, as well as its catalysate PGE2
level in the frontal cortex and hippocampus regions. Chronic cinnamic
aldehyde treatment deceased COX-2 protein and COX-2 activity but not
COX-2 mRNA expression, subsequently resulted in reduction of PGE2
levels in brain. These ﬁndings indicate that cinnamic aldehyde treat-
ment alleviates the depression-like behavior via the COX-2 system in
brain in mid-aged rats. Our results suggest that targeting COX-2 system
might be beneﬁt to the depression, especially elderly individuals.
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